- Trial Phase
- Phase 2a (lead program); no regulatory filings
- Time to Market
- Several years. Phase 2a topline is due late Q3 2026, but this is not a registrational trial — even a positive readout would require a pivotal Phase 3 program and FDA review, so realistic approval is 2029 or later (no BLA/NDA filed; no PDUFA exists).
- Why 8/10
- The single next hard, dated catalyst is the topline readout of the Phase 2a INFORM-MS trial (n=48) in non-active secondary progressive multiple sclerosis, expected late Q3 2026 with a planned presentation at ACTRIMS-ECTRIMS in October 2026 — a near-term binary on Tiziana's lead and essentially only meaningful asset, which justifies an 8.
The stock is a single-asset binary: foralumab Phase 2a INFORM-MS topline data is due late Q3 2026 (ACTRIMS-ECTRIMS presentation in October 2026), and for a ~$126M market-cap company whose lead candidate is its only real program, that readout will likely drive most of the share price for the rest of the year. Insiders (CEO and a 10% holder) have been buying at ~$1.00 and the local analyst consensus is 6 buy/1 hold with a single-analyst mean target of ~$9.03, but a small, non-registrational Phase 2a in a notoriously hard indication is a genuine coin flip — size positions accordingly and watch for financing/dilution between now and the readout.
Price Chart
Executive Summary
Foralumab is Tiziana Life Sciences' (Nasdaq: TLSA) lead — effectively only — asset: an intranasal, fully human anti-CD3 antibody for neuroinflammatory disease, primarily non-active secondary progressive MS. The stock (~$1.13, ~$126M market cap, 52-week range $0.87-$2.35) is trading into a hard binary: Phase 2a INFORM-MS topline data due late Q3 2026 and an ACTRIMS-ECTRIMS presentation in October 2026. Bulls point to insider buying at ~$1.00, a 6-buy/1-hold analyst consensus with a ~$9.03 single-analyst mean target, and encouraging-but-early PET and expanded-access data; bears point to the tiny n=48 non-pivotal trial, non-significant expanded-access results, and heavy single-asset concentration.
How It Works
Foralumab is a fully human monoclonal antibody that targets CD3, a protein on T cells (a type of immune cell). Given intranasally as a nasal spray, it is designed to calm T-cell-driven inflammation inside the brain and central nervous system — the kind of 'neuroinflammation' thought to drive progressive multiple sclerosis and other neurodegenerative conditions — while avoiding the heavy immune suppression of systemic antibody therapy. Tiziana's pitch is a non-invasive, self-administered anti-inflammatory for the brain.
Trial Status
Phase 2a INFORM-MS (NCT06292923, n=48, placebo-controlled) in non-active secondary progressive MS completed enrollment in May 2026; last patient dosed by late June 2026; topline expected late Q3 2026 with presentation at ACTRIMS-ECTRIMS in October 2026. A separate Phase 2 (up to 10 patients) in Multiple System Atrophy has shown PET-imaging reductions in brain inflammation in the first three patients (up to ~34-35% SUV / ~24-26% SUVR reduction). An Expanded Access Program in 14 na-SPMS patients reported good tolerability, one disability progression, and 64% of patients with a clinically meaningful fatigue improvement — not statistically significant at that sample size. Preclinical Long COVID mouse-model data (bioRxiv preprint) showed reduced neuroinflammation and improved cognition.
The Two-Sided Case
Upcoming Catalysts
- INFORM-MS Phase 2a topline data — expected late Q3 2026 (the hard binary)
- ACTRIMS-ECTRIMS meeting presentation of Phase 2a data — October 2026
- Ongoing Phase 2 MSA trial PET/clinical updates
- Potential equity financing / capital raise given pre-revenue cash needs
- Continued expanded-access program updates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Tiziana Life Sciences Ltd 6-K TLSA ·Originating report